Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study Patients with ≥1 prior line of therapy were ...
Please provide your email address to receive an email when new articles are posted on . The FDA is considering a 500 mg subcutaneous initiation dose. Weekly 500 mg autoinjector and biweekly 10 mg/kg ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results